ER Positive Breast Cancer Clinical Trials

29 clinical trials for ER Positive Breast Cancer across international registries, including 12 currently recruiting participants. Compare status, phase, eligibility criteria and locations.

• Supporting Health Including Endocrine Treatment for Long Duration — RECRUITING · NA
• Elacestrant for Treating ER+/HER2- Breast Cancer Patients With ctDNA Relapse (TREAT ctDNA) — RECRUITING · PHASE3
• DATO-BASE: DATOpotamab-deruxtecan for Breast Cancer Brain metAstaSEs — RECRUITING · PHASE2
• Palazestrant in Combination With Ribociclib for the First-line Treatment of ER+/HER2- Advanced Breast Cancer — RECRUITING · PHASE3
• Trial of Pre-operative Neratinib and Endocrine Therapy With Trastuzumab in ER-Positive, HER-2 Positive Breast Cancers — RECRUITING · PHASE2
• Elacestrant + Everolimus in Patients ER+/HER2-, ESR1mut, Advanced Breast Cancer Progressing to ET and CDK4/6i. — RECRUITING · PHASE3
• Fulvestrant+Abemaciclib With Run-In of Fulvestrant in Er-Positive, Her2-Negative Metastatic Breast Cancer — RECRUITING · PHASE2
• Phase 1b Study of OP-1250 (Palazestrant) in Combination With Ribociclib, Alpelisib, Everolimus, or Atirmociclib in ER+, HER2- Breast Cancer — RECRUITING · PHASE1
• Role of the Immune Environment in Response to Therapy in Breast Cancer — RECRUITING
• PRE-I-SPY Phase I/Ib Oncology Platform Program — RECRUITING · PHASE1
• To Identify Primary Resistance to CDK4/6 Inhibitors in Breast Cancer — RECRUITING
• Immunotherapy, Hormone Therapy, and AKT Inhibitor for Premenopausal ER Positive MBC — RECRUITING · PHASE2
• OP-1250 (Palazestrant) vs. Standard of Care for the Treatment of ER+/HER2- Advanced Breast Cancer — ACTIVE_NOT_RECRUITING · PHASE3
• A Phase 1 Study of ATV-1601 in Patients With Advanced Cancer That Have AKT1 E17K Mutations — ACTIVE_NOT_RECRUITING · PHASE1
• Phase II Study of Neoadjuvant ArOMatase Inhibitor Therapy for ER+ Breast Cancer (NAOMI) — ACTIVE_NOT_RECRUITING · PHASE2
• Umbrella Trial of Subtype-Targeted Therapies in ER+/HER2- Breast Cancer — COMPLETED · PHASE2
• Study of Infigratinib in Combination With Tamoxifen in Hormone Receptor Positive, HER2 Negative, FGFR Altered Advanced Breast Cancer — TERMINATED · PHASE1
• A Randomised Trial Comparing Trastuzumab Deruxtecan to CDK4/6 Inhibitors in Non-luminal A, ER-positive/HER2-low Metastatic Breast Cancer — WITHDRAWN · PHASE3
• Levels of Circulating Tumor DNA as a Predictive Marker for Early Switch in Treatment for Patients With Metastatic (Stage IV) Breast Cancer — ACTIVE_NOT_RECRUITING · PHASE2
• A Study of Zilovertamab Vedotin (MK-2140/VLS-101) in Participants With Solid Tumors (MK-2140-002) — TERMINATED · PHASE2
• Study to Evaluate the Extended Overall Survival (OS) Data From PARSIFAL Study (The PARSIFAL-LONG Study) — COMPLETED
• D4 Choline Breast PET/CT — COMPLETED
• Neoadjuvant Treatment of Locally-advanced Breast Cancer Patients With Ribociclib and Letrozole — COMPLETED · PHASE2
• Onapristone and Fulvestrant for ER+ HER2- Metastatic Breast Cancer After Endocrine Therapy and CDK4/6 Inhibitors (The SMILE Study) — TERMINATED · PHASE2
• Fulvestrant + Neratinib In Breast Cancer — WITHDRAWN · PHASE2
• A Study of Neoadjuvant SHR6390 in Combination With Anastrozole, Pyrotinib, and Trastuzumab in Patients With ER+/HER2+ Breast Cancer. — OTHER · PHASE2
• Neoadjuvant Hormonal Therapy Combined With Chemoimmunotherapy — TERMINATED · PHASE1
• AUY922 With Lapatinib and Letrozole for ER+ HER2+ Advanced Breast Cancer — WITHDRAWN · PHASE1
• An Observational Study to Assess Response to Tamoxifen in Breast Cancer Patients — COMPLETED

Refine this search